The second PCAC five: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF
Last updated: November 4, 2026 · 8 min read · By the Grey Peptides Editorial Board
- As of October 27, 2026, FDA's page for the meeting still gives no date; it says only that the committee will meet before the end of February 2027 to discuss LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF.
- FDA's own risk statements: no human exposure data identified for dihexa or PEG-MGF, published case reports of melanoma and other serious harms for melanotan II, and nonclinical signals of harm for LL-37.
- In July the committee recommended 6 of 7 peptides even though, by a law firm's account, FDA scientists recommended against all 7. FDA calls committee votes non-binding recommendations; additions to the list are made by rulemaking.
What the meeting decides, and when
Under section 503A, licensed pharmacies may compound from bulk drug substances that meet one of three conditions: the substance complies with a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA's list of bulk substances for 503A compounding, the '503A bulks list'; FDA adds substances to that list by notice-and-comment rulemaking 1. As of October 22, 2026 the list in the regulation names six substances, none of them a peptide 2. FDA's Pharmacy Compounding Advisory Committee (PCAC) advises the agency on which substances belong on it.
According to a law-firm report, FDA gave notice on April 15, 2026 that it would remove 12 peptides from Category 2, its list of substances raising significant safety risks, after seven days, and would convene the committee in July 2026 and before the end of February 2027 3. FDA's Category 2 page (content current as of April 22, 2026) lists their nominations as withdrawn, without a date 4. The first, on July 23 and 24, 2026, covered seven: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax and epitalon 5. A law firm's summary reports that "In each instance, FDA scientists recommended against inclusion", yet the committee voted to recommend 6 of the 7; only emideltide was voted down, 6 to 7 6. Our July PCAC hub records each vote and what has happened since.
On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157, TB-500, MOTS-c, KPV, semax and epitalon under the forms, routes and conditions in its Appendix B 7. The policy is non-binding, labelled a draft and open to revision; FDA has not added any of them to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).
The second meeting will discuss the remaining five: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor (PEG-MGF). As of October 27, 2026, FDA's meeting page, content current as of April 15, 2026, says only that the time and location will be scheduled in the coming months and that the meeting will happen before the end of February 2027 8. FDA says it intends to make meeting materials available no later than two business days before the meeting 8.
What each file will be judged on
FDA evaluates a substance for the 503A list against four criteria in the regulation: its physical and chemical characterisation; safety issues raised by its use in compounded drugs; the available evidence of effectiveness or lack of it; and its historical use in compounding 2. In July, by the law firm's count, the committee recommended six of the seven by margins such as 8-6-1 and 7-5-2, against FDA scientists' recommendations 6.
What FDA has already published about the five is its risk statement for each, written when they sat in Category 2 or on the list of withdrawn nominations. Those statements are the starting point for any briefing 4:
| Substance | What FDA's risk statement says (page current April 22, 2026) | Human data FDA cites |
|---|---|---|
| Cathelicidin (LL-37) | Possible immune reactions and characterisation problems; animal findings of harm to male reproduction; may promote tumours in some tissues | Not enough to know whether it would cause harm |
| GHK-Cu (injectable routes) | Possible immune reactions from aggregation and peptide-related impurities | Limited |
| Dihexa acetate | FDA lacks important information on any safety issue, including whether it would cause harm | None identified, by any route |
| Melanotan II | Possible immune reactions; published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism | Case reports |
| PEG-MGF | Possible significant immune reactions; impurity and characterisation complexity | None identified, by any route |
For two of the five, dihexa and PEG-MGF, FDA says it has not identified any human exposure data 4.
GHK-Cu: a cosmetic ingredient, reviewed as an injection
GHK-Cu is used as a cosmetic ingredient in anti-wrinkle products 9. The review concerns it as a bulk substance for compounding, and FDA's risk statement concerns injectable routes specifically: possible immune reactions from aggregation and peptide-related impurities, and limited human data 4. Its human evidence is thin. The one small randomised trial on record, in 13 patients after laser resurfacing, found no difference on blinded measures, although patients rated their own skin better 10, and a review found a surprising absence of clinical studies of GHK-Cu, with its anti-wrinkle case resting on cellular studies 9. Our skin and hair hub grades it alongside other cosmetic peptides.
FDA's 503A list, updated May 14, 2026, put non-injectable GHK-Cu back in Category 1 after a nominator clarified that only the injectable route had been withdrawn 11; the human studies above are of topical use.
Melanotan II: the clearest safety record, and not a good one
Melanotan II is the only one of the five that has been given to people in published studies, which is also why it has the clearest record of harm. Its first human study, a single-blind pilot in three healthy men, produced darker skin in two, with spontaneous erections, mild nausea and, in one man, somnolence and fatigue 12. A related melanocortin receptor agonist, bremelanotide, is approved in the US as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women 13. FDA's risk statement cites published case reports of melanoma, posterior reversible encephalopathy syndrome (a form of brain swelling), sympathomimetic toxidrome and priapism 4, and a 2020 case report and review links it to kidney infarction and earlier reports to rhabdomyolysis and kidney failure 14. Vials bought from three online shops held 4.32 to 8.84 mg against a claimed 10 mg, two with 4.1 to 5.9% unknown impurities 15, and users on UK and Irish forums described combining it with sunbeds 16.
Forum users describe using it for tanning 16; for the sexual-desire indication, an approved melanocortin drug already exists 13.
Cathelicidin (LL-37): a natural defence peptide with worrying animal signals
LL-37 is the human cathelicidin, an antimicrobial peptide with antibacterial, antifungal and antiviral activity that also signals to the immune system 17. As a treatment it has been tested topically: on venous leg ulcers, a 34-person trial found significantly faster healing than placebo only at the lowest strength 18 and a 148-person phase 2b trial found no significant healing benefit overall 19, both run by the developer. In mice lacking the mouse version, urinary infections were worse 20.
FDA's risk statement goes beyond the usual immunogenicity concern: nonclinical research suggests detrimental effects on male reproduction, and that LL-37 can promote tumours in some tissues 4. In one cell study, LL-37 at a concentration matching what vitamin D-stimulated immune cells produced reduced the viability of an osteoblast-like cell line 21. Our LL-37 guide covers the trials in more detail.
Dihexa: no human data, and a retracted foundation
Dihexa is a small modified fragment of angiotensin IV sold as a 'cognitive enhancer'. FDA says it has not identified any human exposure data for dihexa by any route and lacks important information on whether it would cause harm 4. Its evidence is in rodents: in a mouse model of Alzheimer's disease it improved spatial learning 22, and in rats it was tested in nerve repair, where muscle injections of stem cells plus dihexa improved walking scores 23. The rat nerve study was co-authored by Joseph Harding, whose laboratory introduced dihexa 23. The 2014 paper from that laboratory tying dihexa to the HGF/c-Met growth-factor pathway (Benoist and colleagues, J Pharmacol Exp Ther 2014) was retracted in April 2025 24; our dihexa safety article covers the retractions.
PEG-MGF: a contested concept with no human exposure
PEG-MGF is the synthetic E-domain fragment of a splice variant of IGF-1, called mechano growth factor, with a polyethylene glycol chain attached to make it last longer. It is sold for muscle growth and recovery. FDA says it may pose a significant risk of immune reactions, has impurity and characterisation complexities, and that FDA has found no human exposure data by any route 4. The unpegylated E peptide has been studied in cultured human muscle cells, where it extended the proliferative lifespan of satellite cells from neonatal and young adult donors but not old ones 25, and the IGF-1 variant it comes from was more abundant in 16 colorectal cancers and 11 polyps than in normal colon tissue 26.
What happens after the vote
A committee recommendation is advice: FDA's meeting pages call advisory committee votes non-binding recommendations 5, and FDA adds substances to the 503A list by notice-and-comment rulemaking 1. As of October 22, 2026 the regulation's list still named no peptide 2, and FDA's categories list, last updated May 14, 2026, predates the July votes 11. The same process will apply to the five in 2027. None of the five is an FDA-approved drug.
We will re-date this page when FDA sets a meeting date, posts briefing documents, or the committee votes. Our legal status checker shows each substance's status across six jurisdictions, and our regulatory tracker follows FDA's actions as they happen.
Frequently asked questions
When is the second PCAC peptide meeting?
As of October 27, 2026, FDA has not set a date. Its meeting page says the committee will meet before the end of February 2027 and that the time and location will be scheduled in the coming months.
Which peptides will the second PCAC review?
Cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor (PEG-MGF), for possible inclusion on the 503A bulks list.
Will GHK-Cu become legal to compound?
Not automatically. Even if the committee recommends it, FDA adds substances to the 503A list by notice-and-comment rulemaking. FDA's risk statement addresses injectable routes; non-injectable GHK-Cu is back in Category 1 of FDA's nominations list.
Does a PCAC vote make a peptide legal?
No. FDA calls the committee's votes non-binding recommendations. In July 2026 it recommended 6 of 7 peptides, but the 503A list in the regulation still names no peptide.
Related on Grey Peptides
Sources
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (three conditions; rulemaking). Content current as of May 14, 2026; read October 27, 2026. FDA
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (paragraphs (a) and (c); eCFR text as of October 22, 2026, read October 27, 2026). eCFR
- Orrick, Herrington & Sutcliffe. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings, April 16, 2026: FDA gave notice on April 15 that 'after 7 days, it will remove 12 peptide bulk drug substances from Category 2', nominations 'withdrawn by the nominators'; removal does not by itself place them on the 503A list or in Category 1. Read October 27, 2026. Cited without a link.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 and withdrawn nominations, listed without a date). Content current as of April 22, 2026; read October 3 and October 27, 2026. FDA
- FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda; 'Advisory committees make non-binding recommendations to the FDA'). Content current as of August 6, 2026; read October 27, 2026. FDA
- McDermott Will & Schulte (law firm). Bulk list bound? PCAC backs majority of peptides in two-day public meeting, July 27, 2026: votes per peptide (BPC-157, KPV and TB-500 8-6-1; MOTS-c 7-5-2; epitalon 7-4-1; semax 8-5-1; emideltide 6-7-1, not recommended) and 'In each instance, FDA scientists recommended against inclusion.' A law-firm summary, not an FDA record; FDA has posted no tallies. Read October 27, 2026. Cited without a link.
- US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
- FDA. Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027): agenda; time and location 'will be scheduled in the coming months'; materials no later than two business days before. Content current as of April 15, 2026; read October 3 and October 27, 2026. FDA
- Mortazavi, S. M., et al. (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts, 15, 30071. PMID: 39963574
- Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
- FDA. Bulk drug substances nominated for use in compounding under section 503A: categories 1-3 (Updated May 14, 2026; GHK-Cu note). Read October 27, 2026. FDA
- Dorr, R. T., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci, 58(20), 1777-84. PMID: 8637402
- Vyleesi (bremelanotide) US prescribing information, section 1 (DailyMed version 1, effective November 13, 2025); read October 27, 2026. DailyMed
- Peters, B., et al. (2020). Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep, 9(2), 159-161. PMID: 31953620
- Breindahl, T., et al. (2015). Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal, 7(2), 164-72. PMID: 24771717
- Gilhooley, E., et al. (2021). Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Dermatology, 237(6), 995-999. PMID: 34464955
- Vandamme, D., et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol, 280(1), 22-35. PMID: 23246832
- Grönberg, A., et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen, 22(5), 613-21. PMID: 25041740
- Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen, 29(6), 938-950. PMID: 34687253
- Chromek, M., et al. (2006). The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med, 12(6), 636-41. PMID: 16751768
- Aidoukovitch, A., et al. (2024). Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochem Biophys Res Commun, 712-713, 149962. PMID: 38642493
- Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci, 11(11). PMID: 34827486
- Weiss, J. B., et al. (2021). Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies. Ann Med Surg (Lond), 71, 102917. PMID: 34703584
- Benoist, C. C., et al. (2025). Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402]. J Pharmacol Exp Ther, 392(4), 103567. PMID: 40312093
- Kandalla, P. K., et al. (2011). Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev, 132(4), 154-62. PMID: 21354439
- Alagaratnam, S., et al. (2020). Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and colorectal cancer. J Cancer Res Clin Oncol, 146(11), 2861-2870. PMID: 32772171
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead